Literature DB >> 8120015

Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant.

G Murphy1, Q Nguyen, M I Cockett, S J Atkinson, J A Allan, C G Knight, F Willenbrock, A J Docherty.   

Abstract

The properties of a deletion mutant delta V191-Q364 of gelatinase A, which represents the removal of the fibronectin-like type II repeats defined by exons 5-7, were compared with those of full-length gelatinase A. Both enzymes underwent self-activation over a similar time course in the presence of 4-aminophenylmercuric acetate. The fully active enzymes had similar kcat/Km values for the cleavage of an octapeptide substrate, but the deletion mutant had 50% of the activity of wild type gelatinase A against beta-casein and 10% of the activity against gelatin. The cleavage pattern for gelatin was similar for both enzymes but differed for type IV collagen. Comparison of the rates of association of the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 and their N-terminal domains to both forms of gelatinase indicated that the fibronectin-like domain plays little role in TIMP binding. The deletion mutant failed to bind to collagen, while the wild type gelatinase bound tightly, indicating that the fibronectin-like domain is the sole site of collagen binding. Both gelatinases could be activated by concanavalin A-activated fibroblasts, suggesting that the fibronectin-like domain is not required for the membrane-mediated activation process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120015

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  The hairpin structure of the (6)F1(1)F2(2)F2 fragment from human fibronectin enhances gelatin binding.

Authors:  A R Pickford; S P Smith; D Staunton; J Boyd; I D Campbell
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

Review 2.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

3.  Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

Authors:  Gillian Murphy
Journal:  Int J Exp Pathol       Date:  2010-08       Impact factor: 1.925

Review 4.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

5.  Thrombin-dependent MMP-2 activity is regulated by heparan sulfate.

Authors:  Bon-Hun Koo; Jung Ho Han; Young Il Yeom; Doo-Sik Kim
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

6.  MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK.

Authors:  Tracy Dodd; Rashmi Jadhav; Luke Wiggins; James Stewart; Erika Smith; James C Russell; Petra Rocic
Journal:  J Mol Cell Cardiol       Date:  2011-08-22       Impact factor: 5.000

Review 7.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

8.  Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2.

Authors:  Xiaoping Xu; Zhihua Chen; Yao Wang; Yoshishige Yamada; Bjorn Steffensen
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

9.  Multiplex detection of protease activity with quantum dot nanosensors prepared by intein-mediated specific bioconjugation.

Authors:  Zuyong Xia; Yun Xing; Min-Kyung So; Ai Leen Koh; Robert Sinclair; Jianghong Rao
Journal:  Anal Chem       Date:  2008-10-16       Impact factor: 6.986

10.  Nuclear magnetic resonance mapping and functional confirmation of the collagen binding sites of matrix metalloproteinase-2.

Authors:  Xiaoping Xu; Margarita Mikhailova; Udayar Ilangovan; Zhihua Chen; Agnes Yu; Sanjay Pal; Andrew P Hinck; Bjorn Steffensen
Journal:  Biochemistry       Date:  2009-06-30       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.